Clinical trials for Rectal cancer

173 currently recruiting clinical trials
Phase 2 Breast cancer Lung cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Thymus cancer Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer Thyroid and adrenal gland cancer Brain tumors / Central nervous system tumors #NCT03175224 #2024-514542-37-00
Cohorte F
Required number of previous lines of therapy
1 2 3 or more
Excluded genetic anomalies
ALK BRAF EGFR KRAS G12C KRAS non G12C MET NTRK-1/2/3 RET ROS-1
Excluded previous treatments
Systemic Treatment-Naive
5 recruiting sites
Apollomics
Phase 2 Prostate cancer Colon cancer Rectal cancer Anal cancer Pancreas cancer Stomach and esophageal cancer Cervical / Vulvar / Vaginal cancer Small intestine and appendix cancer #NCT06333314 #2023-505298-34-00
Required histologic sub types
Neuroendocrine carcinoma
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Immunotherapy Radiotherapy
7 recruiting sites
UNICANCER
Phase 2 Colon cancer Rectal cancer Anal cancer Pancreas cancer Stomach and esophageal cancer #NCT07061080 #2024-514327-42-00
Required histologic types
Stomach Oesogastric junction Esophagus
Required histologic sub types
Neuroendocrine carcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
1
Required previous treatments at advanced or metastatic stage
Chemotherapy
1 recruiting site
Grupo Espanol de Tumores Neuroendocrinos
Phase 2 Colon cancer Rectal cancer #NCT07221357 #2025-523224-45-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Locally Advanced Metastatic
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
Excluded genetic anomalies
BRAF MSI/dMMR
Excluded previous treatments at advanced or metastatic stage
Immunotherapy
6 recruiting sites
Bristol-Myers Squibb
Phase 2 Colon cancer Rectal cancer Anal cancer #NCT04954820
Required histologic sub types
Neuroendocrine tumor
Required number of previous lines of therapy for current stage of disease
1
Required SSTR metabolic imaging statuses
SSTR Positive
Excluded previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
26 recruiting sites
Institut du Cancer de Montpellier - Val d'Aurelle
Phase 2 Colon cancer Rectal cancer Anal cancer #NCT04268121 #2024-515603-19-01
Required histologic sub types
Neuroendocrine carcinoma
Required disease stage
Localized
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
10 recruiting sites
GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer #NCT06581432 #2023-510429-14-00
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
Boehringer Ingelheim
Phase 2 Breast cancer Prostate cancer Colon cancer Rectal cancer Anal cancer Kidney cancer Pancreas cancer Liver and bile duct cancer Bladder / Urinary Tract / Urethral cancer Stomach and esophageal cancer Endometrial cancer Ovarian / Fallopian tubes / Peritoneum cancer Head and neck cancer Sarcoma and GIST Penile cancer and germ cell tumors Cervical / Vulvar / Vaginal cancer #NCT06760819 #2024-517419-62-00
Required histologic types
Stomach Oesogastric junction Esophagus
Required histologic sub types
Adenocarcinoma Intrahepatic cholangiocarcinoma Extrahepatic cholangiocarcinoma Ampullary carcinoma Gastrointestinal stromal tumor Squamous cell carcinoma Other
Required HER2 statuses
HER2 Positive
Required disease stage
Locally Advanced Metastatic Metastatic Castration-resistant
Required genetic anomalies
HER2
Required number of previous lines of therapy for current stage of disease
1
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
6 recruiting sites
Bayer
Phase 2 Colon cancer Rectal cancer #NCT07071844 #2024-520128-27-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Metastatic
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
1 2 3 or more
Required previous treatments at advanced or metastatic stage
Chemotherapy Targeted therapy
Excluded previous treatments at advanced or metastatic stage
Systemic Treatment-Naive
5 recruiting sites
GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie
Phase 2 Colon cancer Rectal cancer #NCT06646445 #2023-509322-22-00
Required histologic sub types
Adenocarcinoma
Required disease stage
Localized
Required genetic anomalies
MSI/dMMR
Required number of previous lines of therapy for current stage of disease
None
Required previous treatments at localized stage
Systemic Treatment-Naive
Excluded previous treatments at localized stage
Immunotherapy
1 recruiting site
GERCOR - Groupe Coopératif Multidisciplinaire d'Oncologie